MS1819 Lipase
- Yeast derived recombinant lipase enzyme
- Oral non-systemic capsule for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis or chronic pancreatitis
- Superior in vitro characteristics (i.e. high potency, activity in long chain fats, stability in protease and bile salt environments) to pig lipase
- Supply chain immune to pandemic infection to pig herds
- Eliminates pork viral contamination risk
- Vegetarian/Kosher/Halal capsules suitable for all patients including those allergic to pig proteins
- Available clinical safety and efficacy profile shows promise
FW-420 and FW-1022 Niclosamide
- Novel anti-inflammatory and anti-viral properties
- Not systemically absorbed
- Allows for higher local GI concentrations
- Avoids steroid-related complications
- Reduced particle size (~7 𝜇𝑚) compared to regular non-micronized (~60 𝜇𝑚) niclosamide
- Smaller particles have greater surface to solvent (GI fluids) ratio
- Improved dissolution: broader distribution and higher local GI concentrations
- Preclinical studies confirm higher GI concentrations (~200x) with micronized niclosamide
- Niclosamide has a historically clean safety profile – approved by the FDA in 1982 and used on millions of patients